The Biden administration has allocated $1.4 billion for the development of experimental COVID-19 vaccines as part of the “Project NextGen” health initiative.
Led by the Administration for Strategic Preparedness and Response (ASPR) and the Biomedical Advanced Research and Development Authority (BARDA), the project aims to prepare the U.S. for future COVID-19 variants and other global health emergencies.
The funding will support clinical trials, next-generation monoclonal antibodies, and new technologies for vaccine manufacturing.
This move adds to the $30 billion already spent by the U.S. government on COVID-19 vaccines.